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ABSTRACT
Effect of supplemental prebiotics, probiotics and bioactive proteins on the microbiome
composition and gut physiology in C57BL6/j mice
by
Ye Li, Master of Science
Utah State University, 2019
Major Professor: Dr. Robert E. Ward
Department: Nutrition, Dietetics, and Food Sciences

The composition and metabolic activity of the microbiome affect many aspects of
health, and there is current interest in dietary constituents that may affect this system. The
purpose of this study was to evaluate the effects of a mix of probiotics, a mix of
prebiotics and a bioactive protein fraction on the microbiome, when fed to mice
individually and in combination. Mice were fed the total western diet (TWD)
supplemented with prebiotics, probiotics, and Tri-Factor (bioactive proteins) individually
and in combination for four weeks. Subsequently, effects on the composition of gut
microbiome, gut short chain fatty acids (SCFAs) concentration, gut inflammation and
integrity of the mucosal barrier were analyzed. Ruminococcus gnavus was increased in
mice gut microbiome after feeding prebiotics. Bifidobacterium longum was increased
after feeding probiotics. Probiotic was associated with higher level of Clostridium
neonatale. The treatments affected beta-diversity with exception of Tri-Factor, but not
alpha diversity of microbiome. All treatments were associated with lower plasma zonulin,
compared to the control group, indicating an effect on gut permeability. There were no
treatment effects on cecal or fecal SCFAs, and the treatments did not affect gut
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inflammation as measured by fecal calprotectin.
(51 pages)
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PUBLIC ABSTRACT

Effect of supplemental prebiotics, probiotics and bioactive proteins on the microbiome
composition and gut physiology in C57BL6/j mice
Ye Li

The composition and metabolic activity of the microbiome affect many aspects of
health, and there is current interest in dietary constituents that may affect this system. The
purpose of this study was to evaluate the effects of a mix of probiotics, a mix of
prebiotics and a bioactive protein fraction on the microbiome, when fed to mice
individually and in combination. Mice were fed the total western diet (TWD)
supplemented with prebiotics, probiotics, and Tri-Factor (bioactive proteins) individually
and in combination for four weeks. Subsequently, effects on the composition of gut
microbiome, gut short chain fatty acids (SCFAs) concentration, gut inflammation and
integrity of the mucosal barrier were analyzed. Ruminococcus gnavus was increased in
mice gut microbiome after feeding prebiotics. Bifidobacterium longum was increased
after feeding probiotics. Probiotic was associated with higher level of Clostridium
neonatale. The treatments affected beta-diversity with exception of Tri-Factor, but not
alpha diversity of microbiome. All treatments were associated with lower plasma zonulin,
compared to the control group, indicating an effect on gut permeability. There were no
treatment effects on cecal or fecal SCFAs, and the treatments did not affect gut
inflammation as measured by fecal calprotectin.

vi

ACKNOWLEDGMENTS

I would like to thank my major professor, Dr. Robert E. Ward, for everything he
has done throughout this research. I appreciate for his trust, patience and immense
knowledge.
I would also like to thank my committee members, Dr. Korry Hintze, and Dr.
Michael Lefevre, for their support insightful comments and support throughout the entire
process.
I would also like to thank all my lab mates, for their expertise, willingness to
answer questions and give guidance. I also would like to thank all the volunteers that
helped with this project.
Finally, I give special thanks to my family, friends, and colleagues for their
encouragement, moral support, and patience as I worked from the initial research to this
final document. I could not have done it without all of you.

Ye Li

vii

CONTENTS
Page
ABSTRACT ....................................................................................................................... iii
ACKNOWLEDGMENTS ................................................................................................. vi
CONTENTS ...................................................................................................................... vii
LIST OF TABLES ........................................................................................................... viii
LIST OF FIGURES ........................................................................................................... ix
LIST OF ABBREVIATIONS AND SYMBOLS ................................................................x
I.

INTRODUCTION ........................................................................................................1

II. METHOD AND MATERIALS ....................................................................................8
Diet formulation ....................................................................................................................... 8
Study design ........................................................................................................................... 11
Diet probiotic enumeration .................................................................................................... 12
SCFAs analysis ...................................................................................................................... 12
Gut Microbiome ..................................................................................................................... 12
Gut inflammation ................................................................................................................... 13
Plasma zonulin ....................................................................................................................... 13
Statistics analysis ................................................................................................................... 14

III. RESULTS ...................................................................................................................15
Diet probiotic content ............................................................................................................ 15
Food intake, weight gain, metabolic efficiency and probiotic intake. ................................... 15
SCFAs .................................................................................................................................... 16
Microbiome ............................................................................................................................ 18
Gut inflammation ................................................................................................................... 22
Gut permeability .................................................................................................................... 23

IV. DISCUSSION .............................................................................................................24
V. CONCLUSION...........................................................................................................28
VI. REFERENCES ...........................................................................................................29

viii

LIST OF TABLES
Table

Page

1

Translation of human to mouse intakes using nutrient density .......................... 8

2

Composition of experimental diets ................................................................... 10

3

Probiotic enumeration for diets, and estimated probiotic intake/d ................... 15

4

Food intake, weight gain, and metabolic efficiency ......................................... 16

5

SCFAs in cecal and fecal samples for treatments............................................. 17

6

Significant effect of treatment on taxonomic abundance compared to TWD .. 20

ix

LIST OF FIGURES
Figure

Page

1

Study design for dietary supplement ................................................................. 11

2

SCFAs analysis, data represent as mean ±SE (mol/g). A, butyric acid in cecal
samples, p=0.044. B, caproic acid in cecal samples, p=0.022. C, acetic acid in
fecal samples, p=0.025. D, butyric acid in fecal samples, p=0.037. ................. 18

3

Family level taxonomy, percentage of total OTUs............................................ 19

4

Alpha-diversity of gut microbiome, expressed by OTUs. A, PRE vs TWD,
p=0.243: B, PRO vs TWD, p=0.673: C, TF vs TWD, p=0.277: D, COM vs
TWD, p=0.720 ................................................................................................... 21

5

Beta-diversity of gut microbiome, unweighted unifrac distance with nonparametric PERMANOVA test. A, PRE vs TWD, p=0.021: B, PRO vs TWD,
p=0.015: C, TF vs TWD, p=0.415: D, COM vs TWD, p=0.005....................... 22

6

Fecal calprotectin. Data represent mean ±SE (g/g) ....................................... 23

7

Plasma zonulin. Data represent mean ±SE (ng/ml). Different letters represent
significant difference in ANOVA analysis. ....................................................... 23

x

LIST OF ABBREVIATIONS AND SYMBOLS
Abbreviations

Symbols

ANOVA Analysis of variance

Kg

kilogram

CFU

Colony forming unit

g

gram

COM

Combination group

mg

milligram

DNA

Deoxyribonucleic acid

µg

microgram

ELISA

Enzyme-linked immunosorbent assay

ng

nanogram

FOS

Fructooligosaccharides

ml

milliliter

GOS

Galactooligosaccharides

M

molar

IBD

Inflammatory bowel diseases

mmol

micromolar

OTU

Operational taxonomic unit

d

day

PCR

Polymerase chain reaction

kcal

kilocalorie

PGM

Personal Genome Machine

n

number

PRE

Prebiotic group

ºC

degrees Centigrade

PRO

Probiotic group

SCFAs

Short-chain fatty acids

SE

Standard error

TF

Transfer factor group

TLR

Toll-like receptor

TWD

Total Western diet

USU

Utah State University

XOS

Xylooligosaccharides

I. INTRODUCTION
Prebiotics and probiotics are two common dietary supplements that have been
shown to affect gut health in both rodent and human studies. Prebiotics are substrates that
are utilized by select gut microorganisms, and which confer a health benefit (Gibson et
al., 2017; Gibson, Probert, Van Loo, Rastall, & Roberfroid, 2004). Probiotics are bacteria
that improve gut health, and which come predominantly from the Lactobacillus and
Bifidobacterium genera (Colin Hill et al., 2014; C. Hill et al., 2014; Mack, 2005). Most
prebiotics are oligosaccharides, which pass undigested through the small intestine to the
colon and are fermented by intestinal bacteria and stimulate the growth of specific
microbial taxa (Blaut, 2002; Rastall, 2010; Roberfroid, 2007). Probiotics are added as
culture of fermented foods like yogurt and kefir or naturally present as starter on
vegetable for kimchi and sauerkraut. They are also taken as supplements for human.
There have been many model rodent and human clinical studies that have
investigated the health benefits of prebiotics, probiotics and/or synbiotics (prebiotics and
probiotics administered together). Such health benefits include promotion of gut
fermentation, modulation of the microbiome composition, reduction of gut inflammation,
decreased susceptibility to food allergy and prevention of cancer (I. Cho & Blaser, 2012;
Swennen, Courtin, & Delcour, 2006). Suggested benefits of probiotics include
improvement of the gut barrier function, increased competitive adherence to the mucosa
and epithelium, gut microbiota modification, and regulation of the gut associated
lymphoid immune system (Saez-Lara, Robles-Sanchez, Ruiz-Ojeda, Plaza-Diaz, & Gil,
2016).
In mice, many studies have reported large increases in cecal and fecal SCFAs
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with prebiotic inclusion in the diet, which is likely due to the quantity. For example,
mouse diets are often supplemented with 5-10% prebiotics (B. S. Hamilton et al., 2017;
Murakami et al., 2015a; Nihei et al., 2018; Weitkunat et al., 2015a). Hamilton et al fed
10% inulin or bovine milk oligosaccharides to mice on a high fat diet (4500 kcal/kg)
which increased cecal butyrate and propionate (B. S. Hamilton et al., 2017). Weitkunat
supplemented a high-fat diet in mice with 10% inulin, and acetate, propionate and
butyrate were all increased in the cecum, as were total SCFAs (Nihei et al., 2018). Nihei
et al include 5.5% cyclodextrin to a high-fat diet (~5250 kcal/kg) which was associated
with an increase in all cecal SCFAs except n-valeric acid. Last, Murakami added 10%
epilactose to both low and high fat diets which increase all cecal SCFAs except lactic
acid (Murakami et al., 2015b). In the studies above, prebiotics were associated with
impressive health benefits. For example, supplementation prevented adiposity
development (B. S. Hamilton et al., 2017; Nihei et al., 2018), gut permeability (M. K.
Hamilton et al., 2017), improved lipid metabolism (Nihei et al., 2018; Weitkunat et al.,
2015b), and increased energy expenditure (Murakami et al., 2015b; Nihei et al., 2018).
In human trials, prebiotics are typically supplemented between 5 and 20 g/d
(Childs et al., 2014; Finegold et al., 2014; Holscher et al., 2015; Lecerf et al., 2012;
Rajkumar et al., 2015; Vandeputte et al., 2017; Wilms et al., 2016). Fecal SCFAs have
been measured in some studies, and to date a clear effect has not been established. No
change in fecal SCFAs was determined after 1.4 or 2.8 g/d XOS for 8 weeks (Finegold et
al., 2014), or 5 and 7.5 g/d inulin for 21d (Holscher et al., 2015). Conversely,
consumption of 5g/d XOS for 4 weeks increased fecal butyrate and decreased acetate,
while a mix of 3g/d inulin and 1g/d XOS resulted in an increase in propionate and total

3

SCFAs (Lecerf et al., 2012). Childs et al provided subjects with 8g/d XOS and 109 CFU
Bifidobacterium animalis subspecies lactis Bi-07, singly and in combination for 21d
(Childs et al., 2014). Individually, both treatments reduced fecal acetate and butyrate, but
the combination did not. In addition, the combination increased fecal iso-valeric acid. At
higher intakes, prebiotics supplementation has been shown to increase fecal SCFAs, but
is also associated with an increase in gastrointestinal stress. Clarke et al fed subjects
either 3 ×5 g/d of a mixture of inulin and FOS or maltodextrin for 28d (Clarke et al.,
2016). The prebiotic supplementation significantly increased total fecal SCFAs, but was
associated with significant increases in self-reported GI symptoms and headaches. More
concerning, however, is the fact that the 15g/d prebiotic supplementation increased
circulating inflammatory cytokines, the proportion of immune cells that expressed TLR2
and TLR4, and the response to TLR2 agonists in an ex vivo assay. The authors suggested
that increases in these markers, while moderate, were consistent with increased immune
cell contact with microbial stimuli.
Rodent studies suggest that substantial intakes of prebiotics may improve
metabolic health, yet it is unclear if such levels can be achieved in human diets. To date,
there has been little discussion in the literature on translating intakes of prebiotics
between rodents and humans. A 25 g mouse consuming 2.5 g of food a day with 10%
prebiotics will ingest 0.25 g, or 10g/kg. For a 70 kg, that translates to 700g of prebiotics
per day. However, if nutrient density is used and the prebiotics are normalized to kcal,
2.5g of a high fat diet (5000 kcal/g) with 10% prebiotics would deliver 20 mg/kcal. For a
2500 kcal diet, an equivalent intake would be 50g/d, which is significantly higher than
the Institute of Medicine’s recommendation for total dietary fiber, which is 14g/1000 kcal
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(Institute_of_Medicine, 2005).
The effects on gut microbiome were observed when administered only probiotics
or combined with prebiotics. The changes in gut microbiome can contribute to an
increased susceptibility to diseases both within and outside the gut (Cénit, Matzaraki,
Tigchelaar, & Zhernakova, 2014). There have been a number of studies that have shown
modification of gut microbiome when mice are supplemented with large doses of
prebiotics, probiotics, individually or in combination (Carasi et al., 2015; W. Cheng et al.,
2017; W Cheng et al., 2018; Cortez-Pinto et al., 2016; Delbes et al., 2018; Foure et al.,
2018; Frece et al., 2009; Mariman, Tielen, Koning, & Nagelkerken, 2015; Nihei et al.,
2018; Singh et al., 2017; Wang et al., 2012). Changes are typically an increase in
abundance of fecal Bifidobacteria, Lactobacilli and Alloprevotella (W. Cheng et al.,
2017; W Cheng et al., 2018; Delbes et al., 2018; Frece et al., 2009; M. K. Hamilton et al.,
2017; Mischke et al., 2018; Nihei et al., 2018; Singh et al., 2017). The Firmicutes /
Bacteroidetes ratio has also been affected by treatments (Foure et al., 2018). An increased
ratio of Firmicutes to Bacteroidetes was observed in obese versus lean subjects (Cénit et
al., 2014; Turnbaugh et al., 2008).
In general, the effectiveness of probiotics and prebiotics have been more
substantial in rodent studies. Several factors may explain the inconsistence in results
between mice and humans, including 1) the specific prebiotics and probiotics
administered, 2) the method of delivery, 3) the duration of treatment, 4) the dosage used,
and 5) fundamental differences between the two species.
In rodents, prebiotic supplementation of diets is common at levels between 5.5%
and 15% on a mass basis (W. Cheng et al., 2017; Delbes et al., 2018; M. K. Hamilton et
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al., 2017; Nihei et al., 2018), which is high, considering total dietary fiber in the purified
rodent diet, the AIN-93G, is only 5% by mass. In human studies, prebiotics have been
given at levels between 5 to 20 g/day (Childs et al., 2014; Clarke et al., 2016; Finegold et
al., 2014; Holscher et al., 2015; Lecerf et al., 2012; Rajkumar et al., 2015; Vandeputte et
al., 2017; Wilms et al., 2016). A possible explanation for differences in results between
rodent and human studies may be the amount given, yet there has not been much
discussion in the literature of how to translate prebiotic intakes between species. If
dosage levels are compared on a gram of prebiotic consumed per kilogram of body
weight in mice and humans, the levels are approximately 60 times higher in rodent
studies. Yet, body weight normalization does not take into account the increased
metabolic rate of rodents. Allometric scaling is a method of interspecies comparison of
basal nutrient requirements (Rucker, 2007), and may be more appropriate for translating
intakes between species. One method of allometric scaling is nutrient density, wherein
nutrients are expressed relative to calories. If the nutrient density of prebiotic
supplementation is compared (mg prebiotic/kcal diet), then rodent studies typically
supply 3-4 fold more that the human studies.
In rodent studies, probiotics have been given in a range of 108 and 109 CFU/day
for mice (Bai et al., 2016; Carasi et al., 2015; Mariman et al., 2015; Wang et al., 2012),
and around 109 CFU/day for humans (Childs et al., 2014; Gargari et al., 2016; Lee et al.,
2017; Rajkumar et al., 2015; Rungsri et al., 2017; Seo et al., 2017; Toscano, De Grandi,
Stronati, De Vecchi, & Drago, 2017; van Zanten et al., 2014). If probiotic intakes
between rodents and humans are compared on a mass basis (i.e. 109 CFU for 75kg human
vs. 108 CFU for 25g mouse), rodents are typically given ~150X more. When CFUs are
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normalized to calorie intake (i.e. i.e. 109 CFU for 2500 kcal/d human vs. 108 CFU for 11
kcal/d mouse), rodents are given ~10X more. In rodent studies, probiotics may be mixed
in the food pellets (Delbes et al., 2018; Nihei et al., 2018) or administered via oral gavage
(Carasi et al., 2015; Foure et al., 2018; Mariman et al., 2015; Singh et al., 2017; Wang et
al., 2012). Additionally, probiotics have be added to the drinking water of the rodents
(Bai et al., 2016; Umu et al., 2016). The advantage for oral gavage is the precise control
of dosage, when compared to inclusion in the food or water.
Tri-Factor® is a proprietary blend of low molecular weight bioactive proteins
isolated from bovine colostrum and egg yolks (www.4life.com). Tri-Factor contains two
ultra filtrates of colostrum, one with a molecular weight cut off of 10 kDa, and a second
at 3 kDa. Low molecular weight colostrum proteins and peptides are rich in proline, and
low in glycine, alanine, arginine and histidine, and do not contain tryptophan, methionine
or cysteine (Szaniszlo et al., 2009).
The overall objective of this study was to evaluate the effect of a human gut
health supplement in a mouse model when provided at a physiologically relevant dose.
As a control, mice were fed the TWD, a purified rodent diet that matches the average US
intake of macro- and micronutrients (Hintze, Benninghoff, Cho, & Ward, 2018). The
TWD was supplemented with either prebiotics, probiotics, or Tri-Factor, individually and
in combination. The endpoints of interest were the effect on the composition of the gut
microbiome, cecal and fecal short chain fatty acids (SCFAs), gut inflammation, and
plasma zonulin.
The overall hypothesis is that the treatments will increase the diversity of the
microbiome and be associated with more SCFAs, less gut inflammation and an improved
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mucosal barrier. Specifically, we predict the prebiotics treatment will increase the fecal
microbiome diversity, the cecal SFCAs content and decrease fecal calprotectin. We
anticipate the probiotics treatment will increase the fecal levels of the probiotics
administered and reduce fecal calprotectin. The TF treatment will affect the microbiome
composition, and the levels of gut inflammation. Last, the combined treatment is predicted
to increase both the fecal microbiome diversity and SCFAs due to the presence of the
probiotics and prebiotics, while it will reduce fecal calprotectin.
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II. METHOD AND MATERIALS
Diet formulation
The treatment dosages were calculated using a nutrient density approach to
convert the dosage of the human supplement (Pre/o Biotics, 4Life, Sandy, UT) to
metabolically equivalent doses in mice (Table 1) The supplement, Pre/o Biotics contains
2.5g of prebiotics with equal parts fructooligosaccharides (FOS), galactooligosaccharides
(GOS) and xylooligosaccharides (XOS). In addition, Pre/o Biotics contains 0.5 × 109
CFU of Bifidobacterium infantis (M-63), Bifidobacterium longum (BB536) and
Bifidobacterium lactis (Bl-04), and 0.25 × 109 CFU Lactobacillus rhamnosus (Lr-32) and
Lactobacillus acidophilus (NCFM). Last, Pre/o Biotics contains 100 mg of Tri-Factor, a
proprietary concentrate of egg yolk and bovine colostrum proteins and peptides (4life,
Sandy, UT).
Table 1. Translation of human to mouse intakes using nutrient density
Nutrient intake
Pre/o Biotics
Human

Mice

§

Prebiotics

Probiotics

Tri-Factor

2.5 g/d

2 × 109 CFU/d

100 mg/d

Energy intake (kcal/d)

2500

2500

2500

Nutrient density

1 mg/kcal

8 × 105 CFU/kcal

40 µg/kcal

Translated dose

11 mg/d

Energy intake (kcal/d)

11

11

11

Nutrient density

1 mg/kcal

8 × 105 CFU/kcal

40 µg/kcal

Actual dose§

16.5 mg/d

1.3 × 107 CFU/d

0.66 mg/kcal

supplement

8.8 × 106
CFU/kcal

0.44 mg/d

The prebiotic and Tri-Factor were increased by 1.5-fold and the probiotics by 3-fold to

increase likelihood of measurable effects
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To convert the dosages using nutrient density, an average caloric intake of 2,500
kcal/day was used for humans. For mice, 11 kcal was determined according to previous
studies. The quantities of prebiotics, probiotics and Tri-Factor in Pre/o Biotics were
normalized to an average human caloric intake (i.e. 2.5g prebiotics/2500 kcal = 1
mg/kcal). This value was then used to determine the mass added to the TWD formulation,
which has a 4400 kcal per kilogram. For the prebiotics, there should be 4.4 g of prebiotics
per kg of diet (i.e. 1 mg/kcal * 4400 kcal), and similar calculations were made for the
probiotics and Tri-Factor. To increase the likelihood of measuring treatment effects, the
dose of prebiotics and Tri-Factor was increased 1.5-fold, and the probiotic treatment 3fold (Table 1).
The control diet was the TWD, and for the treatment groups, a portion of
maltodextrin was removed to account for the prebiotic, probiotic and Tri-Factor addition.
The decision to replace maltodextrin was made as it has most often been used as a control
in human prebiotic studies (Beserra et al., 2015; Fernandes, do Rosario, Mocellin, Kuntz,
& Trindade, 2017). Diet assignments were as follows: 1) TWD: Total Western Diet as
control: 2) PRE: prebiotics, 3) PRO: probiotics, 4) TF: Tri-Factor, 5) COM: prebiotics,
probiotics and Tri-Factor. The composition of the diets is shown in Table 2. All diets
were stored with vacuum package at -20C until provided for feeding.
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Table 2. Composition of experimental diets
Diet composition

TWD

PRE

PRO

TF

COM

-

6.75
-

0.15
-

0.26

6.75
0.15
0.26

30
230.0
70.0
261.3

30
230.0
63.2
261.3

30
230.0
69.7
261.3

30
230.0
69.6
261.3

30
230.0
62.7
261.3

190
2.85

190
2.85

190
2.85

190
2.85

190
2.85

36.3
24.8
0.4
16.5
28
28
31.4

36.3
24.8
0.4
16.5
28
28
31.4

36.3
24.8
0.4
16.5
28
28
31.4

36.3
24.8
0.4
16.5
28
28
31.4

36.3
24.8
0.4
16.5
28
28
31.4

35
10
4
1.4
0.028

35
10
4
1.4
0.028

35
10
4
1.4
0.028

35
10
4
1.4
0.028

35
10
4
1.4
0.028

Protein
Carbohydrate
Fat

15.5
50.0
34.5

15.5
49.7
34.7

15.5
50.0
34.5

15.5
50.0
34.5

15.5
49.7
34.7

Calorie (Kcal/g)

4.4

4.3

4.4

4.4

4.3

Treatment (g/kg)
Prebiotic §
Probiotic
Tri-Factor
Carbohydrate (g/kg)
Cellulose
Corn starch
Maltodextrin ‡
Sucrose
Protein (g/kg)
Casein
L-cysteine
Fat (g/kg)
Anhydrous milk fat
Beef tallow
Cholesterol
Corn Oil
Lard
Olive oil
Soybean oil

Vitamin, mineral, antioxidant (g/kg)
Mineral mix
Vitamin mix
Sodium chloride
Choline bitartrate
TBHQ
% Kcal

§

The prebiotics contained equal parts FOS, GOS and XOS.
Prebiotics, probiotics and Tri-Factor additions were balanced by removing
maltodextrin.
‡
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Study design
C57Bl/6J male mice were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice were randomly assigned by weight to each treatment for 4 weeks. Mice were
individually housed in HEPA-filtered micro isolator cages. A 12-hour light/dark cycle
was used, and the room temperature was kept between 18-23°C with humidity between
20-50%. All animal care and husbandry procedures were performed under the Animal
Welfare Act and the Public Health Service Policy on Humane Care and Use of
Laboratory Animals, as well as USU Institutional Animal Care and Use Committee
(protocol #2640). The experimental design is shown in Figure 1.
TWD: total western diet (n=9)

C57BL6J
Mice
(N=49)

PRE: prebiotics group(n=10)

FOS, GOS, XOS

PRO: probiotics group (n=10)

B. infantis, B. longum, B. lactis, L.
rhamnosus, L. acidophilus

TF: Tri-Factor group (n=10)
COM: combination group
(n=10)

PRE+PRO+TF

Figure 1. Study design for dietary supplement
Food intake and body weight were measured twice weekly. At the end of
intervention, mice were killed by CO2 asphyxiation. Blood was removed by cardiac
puncture and plasma was separated from whole blood via centrifugation. Plasma was
aliquoted into microcentrifuge tubes and snap frozen in liquid nitrogen. Both fecal and
cecal samples were collected at the end of intervention and snap frozen in liquid nitrogen
and stored at -80°C until analysis.
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Diet probiotic enumeration
Diet samples were sent to Covance Laboratory (Madison, WI) for Total Probiotic
Enumeration using standard plate procedures (Schoeni, 2013).
SCFAs analysis
SCFAs were extracted from fecal and cecal samples at the end of intervention,
and measured by gas chromatography with flame ionization detection (GC-FID)
according to the method from Ward et al (Ward et al., 2016).
Gut Microbiome
Taxonomic measures of the fecal microbiome were performed using 16s rRNA
sequencing. The fecal samples collected at the terminal necropsy were used for this
analysis. Bacterial DNA from the fecal samples was extracted using the QIAGEN
QIAamp DNA Stool Mini Kit (Hilden, Germany) according to the manufacturer’s
instructions. This extraction process involves homogenization and lysis of the stool using
a stool lysis buffer and bead beater, and removal of inhibitors.
After DNA extraction, samples were analyzed by spectroscopy to determine the
concentration of DNA for each sample and then diluted with TE buffer to a concentration
of 1 ng/µL. Samples were amplified via PCR, using barcoded primers directed against the
V3 region of the 16S rRNA (Milani et al., 2013). PCR amplification was performed using
the following protocol: 5 minutes at 95°C; 35 cycles of 94°C for 30 seconds, 55°C for 30
seconds and 72°C for 90 seconds; final annealing at 72°C for 10 minutes; hold at 4°C.
Following PCR amplification, gel electrophoresis was performed to visualize
amplicons. The PCR products were then purified using AMPure microbeads. Once all the
samples were purified, DNA concentration was assessed using the Picogreen assay,
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which measures fluorescence via spectrophotometry to determine DNA concentration.
Samples were then diluted to 1 ng/µL with TE buffer and pooled together into a single
tube. Sequencing was performed at the Utah State Center for Integrated Biotechnology
core sequencing facility using the Ion PGM System and analyzed using Ion Reporter™
workflow.
Sequences were processed with the latest version of MacQIIME (Caporaso et al.,
2010). Sequences were filtered for quality and assigned operational taxonomic units
(OTUs) (Schloss et al., 2009) at a 97% sequence similarity as compared to a reference
GreenGenes OTU database (gg_13_8_otus). Sequences were assigned using the openreference OTU picking methodology with UCLUST (DeSantis et al., 2006). Sequences at
the highest levels of abundance were chosen as representative sequences, and these were
checked for chimeras using uchime61 (Edgar, Haas, Clemente, Quince, & Knight, 2011).
Alpha diversity, beta diversity, and taxonomic summaries were performed using the
core_diversity_analyses.py script. For diversity analyses, sequence depth was rarified to
the sample with the fewest sequences.
Gut inflammation
Fecal calprotectin was extracted by with the following extraction buffer: 0.1 M
Tris, 0.15 M NaCl, 1.0 M urea, 10 mM CaCl2, 0.1 M citric acid monohydrate and 5 g/L
BSA (pH 8.0). After extraction and centrifugation, the supernatant was used for the
ELISA analysis with a commercial kit following manufacturer’s instructions (Hycult Inc,
Wayne, PA).
Plasma zonulin
Plasma samples were analyzed using a commercial ELISA kit according to
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manufacturer’s directions (MyBioSource, San Diego, CA).
Statistics analysis
Treatment effects and interactions were determined by one way-ANOVA with
Dunnett’s test. Pairwise analysis was used in microbiome results to compare each
treatment with TWD group. For all statistical tests, a p value <0.05 (two-tailed test) was
considered as significant. Transformations were used to equalize variance prior to the
statistical analyses in cases where variance assumptions were not met.
Because microbiome taxonomy data typically are not normally distributed due to
zero-inflation, the effects of diet on relative taxonomic abundance were determined
separately as one-way, non-parametric analyses. For these analyses, OTUs were
normalized to sequences per million for each sample and then merged by the highestlevel classification (to species, if available), family, and phylum taxonomy levels. Single
factor comparisons (PRE, PRO, TF, and COM vs TWD) at the phylum, family, and
genus level were then made and tested for significance using the Kruskal-Wallis test and
results corrected for multiple testing effects by the false discovery rate (FDR) test.
Statistical analysis of beta diversity data was performed using the non-parametric
PERMANOVA measure, which partitions a distance matrix among sources of variation
in order to describe the strength and significance that an experimental variable has in
determining variation of distances.
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III. RESULTS
Diet probiotic content
The probiotics were added to the PRO and COM diets as powders, and plate
counts were conducted by a third party to enumerate the CFUs in each diet. These
numbers were then used to determine the average probiotic intake for each diet (Table 3).
In the TWD and TF diets, the probiotic plate counts were below the detection limit of the
assay, which is not surprising, as probiotics were not added to the diets. The PRE diet did
contain a measurable level of probiotics, which presumably were introduced in the
prebiotic powders. The COM diet contained the highest level of probiotics, followed by
the PRO diet.
Table 3. Probiotic enumeration for diets, and estimated probiotic intake/d
Treatment

TWD

PRE

PRO

TF

COM

CFU/g diet

<1 × 104

2 × 104

9 × 104

<1 × 104

3.4 × 105

CFU/d‡

<2.4 × 104

5.5 × 104

2.6 × 105

<2.7 × 104

9 × 106

‡

Probiotic intake was estimated using CFU/g content measured in diets and average

mass of food consumed per group.
Food intake, weight gain, metabolic efficiency and probiotic intake.
Mice consumed significantly more calories on the PRO diet than the TWD (Table
4), but there were no other differences in intake among the diets. There was no treatment
effect on weight gain, nor metabolic efficiency, which is the mass gain per calorie.
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Table 4. Food intake, weight gain, and metabolic efficiency
Treatment
Energy intake
(Kcal/day)
Weight gain (g)
Metabolic efficiency
(g/kcal)

TWD

PRE

PRO

TF

COM

10.8±0.2a

12.1±0.2ab

12.9±0.5b

12.2±0.4ab

11.7±0.4ab

6.6±0.5

8.0±0.5

7.7±0.5

6.4±0.4

7.4±0.6

0.61±0.04

0.66±0.04

0.60±0.04

0.53±0.03

0.63±0.05

Values with different superscripts differed significantly (p<0.05).
SCFAs
There were very few differences in the SCFAs content of the cecal or fecal
contents (Table 5). In the cecal contents, only caproic acid differed significantly between
the treatments, with all treatments being higher than the control. In feces, there was a
trend (p<0.1) for differences in iso-butyric and valeric acids.
When the TWD and COM treatments are compared directly, there was more
butyric and caproic acid in the cecal contents, and more acetic and butyric acid in the
fecal content (Figure 2).
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Table 5. SCFAs in cecal and fecal samples for treatments
Cecal SCFAs

p-

TWD

PRE

PRO

TF

COM

Acetic acid

27.8±2.1

26.3±2.5

26.4±1.7

28.9±2.1

28.3±1.3

Propionic acid

3.87±0.28 3.88±0.29 4.58±0.30 4.11±0.28 4.61±0.33 0.22

n-Butyric acid

3.02±0.30 3.30±0.43 3.38±0.23 3.62±0.35 4.00±0.35 0.33

iso-Butyric acid

0.48±0.01 0.44±0.03 0.47±0.01 0.44±0.02 0.47±0.01 0.47

iso-Valeric acid

0.53±0.01 0.49±0.02 0.51±0.02 0.51±0.03 0.52±0.03 0.79

n-Valeric acid

0.51±0.02 0.48±0.04 0.49±0.04 0.52±0.05 0.52±0.03 0.86

Caproic acid

0.05±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.06±0.01 0.05

(mol/g)

Fecal SCFAs

value
0.84

p-

TWD

PRE

PRO

TF

COM

Acetic acid

20.4±2.1

28.0±2.5

25.5±4.5

22.8±1.8

27.2±1.9

0.27

Propionic acid

2.2±0.3

2.6±0.2

2.1±0.3

2.6±0.3

2.8±0.2

0.20

n-Butyric acid

0.70±0.10 0.97±0.17 0.87±0.08 1.05±0.12 1.03±0.10 0.26

iso-Butyric acid

0.26±0.03 0.37±0.04 0.25±0.03 0.35±0.05 0.32±0.02 0.06

iso-Valeric acid

0.43±0.05 0.58±0.05 0.45±0.03 0.55±0.07 0.52±0.02 0.21

n-Valeric acid

0.19±0.03 0.26±0.04 0.14±0.02 0.31±0.08 0.19±0.02 0.10

Caproic acid

0.06±0.01 0.17±0.06 0.09±0.02 0.20±0.10 0.11±0.03 0.39

(mol/g)

value

SCFAs are expressed as mean ±SE (mol/g). P-value was calculated by one-way
ANOVA.
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Figure 2. SCFAs analysis, data represent as mean ±SE (mol/g). A, butyric acid in cecal
samples, p=0.044. B, caproic acid in cecal samples, p=0.022. C, acetic acid in fecal
samples, p=0.025. D, butyric acid in fecal samples, p=0.037.
Microbiome
Taxonomic Summaries
After quality, chimera, and abundance filtering, sequences were assigned to OTUs
using the pick_open_ref_otus command for an average of 46853 sequences per sample
assigned to 1546 OTUs. Compared to diet, PRE, PRO and COM treatments changed the
microbiome composition. Figure 3 showed the family level taxonomy.
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Figure 3. Family level taxonomy, percentage of total OTUs
Because the differences in taxonomic relative abundance did not follow a normal
distribution, these analyses were performed using non-parametric, single factor
comparisons. A complete summary of significant differences in relative abundance is
given in Table 6.
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Table 6. Significant effect of treatment on taxonomic abundance compared to TWD
Taxonomic Abundance

p-value, each group compared to TWD)
PRE

PRO

TF

COM

Direction*

Class

Actinobacteria

/

0.0059

/

/

PRO

Order

Bifidobacteriales

/

0.0047

/

0.0226

PRO, COM

Family

Bifidobacteriaceae

/

0.0078

/

0.0438

PRO, COM

Ruminococcus

0.0065

/

/

/

PRE

Bifidobacterium

/

0.0081

/

/

PRO

gnavus

0.0004

/

/

0.0017

PRE, COM

/

0.0019

/

0.0069

PRO, COM

/

0.0321

/

/

PRO

Genus

Species longum
neonatale

*Note: Direction denotes a greater relative abundance in the study group mentioned
Ruminococcus gnavus was increased after feeding prebiotics. The increasing was
observed both in PRE and COM. Bifidobacterium longum was increased in mice gut
microbiome after feeding probiotics. The increasing of Bifidobacteriaceae was consistent
in PRO and COM. Besides, PRO was associated with higher level of Clostridium
neonatale.
Microbiome diversity
Alpha diversity refers to within-habitat diversity. It is the component of total
diversity that can be attributed to the average number of species found within
homogeneous sampling units (i.e. habitats) (Gering & Crist, 2002). Alpha diversity was
determined using Chao1 index. The analyses showed that no significant difference
affected by diets in Figure 4. All treatments did not affect alpha-diversity.

21

A. PRE vs TWD

B. PRO vs TWD

C. TF vs TWD

D. COM vs TWD

Figure 4. Alpha-diversity of gut microbiome, expressed by OTUs. A, PRE vs TWD,
p=0.243: B, PRO vs TWD, p=0.673: C, TF vs TWD, p=0.277: D, COM vs TWD,
p=0.720
Beta diversity is referred to between-habitat diversity. It is the component of total
diversity that can be attributed to differences in species composition among the
homogeneous units in the landscape (Gering & Crist, 2002). Figure 5 is a spatial
representation of beta diversity with Principle Coordinate Analysis. The treatment
affected beta-diversity with exception of TF.
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A. PRE vs TWD

B. PRO vs TWD

C. TF vs TWD

D. COM vs TWD

Figure 5. Beta-diversity of gut microbiome, unweighted unifrac distance with nonparametric PERMANOVA test. A, PRE vs TWD, p=0.021: B, PRO vs TWD, p=0.015:
C, TF vs TWD, p=0.415: D, COM vs TWD, p=0.005
Gut inflammation
The effect of diets on fecal calprotectin is shown in Figure 6. Prior to being
randomized to the treatments, fecal samples were collected from mice consuming a
standard laboratory chow diet. According to the data, mice consuming chow had lower
levels of fecal calprotectin than mice on any of the treatment diets. After 4-week
intervention on TWD and other treatments, mice showed higher level of fecal
calprotectin. In comparison within treatments, there was no effect among the test diets
(p=0.1355).
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Figure 6. Fecal calprotectin. Data represent mean ±SE (g/g)
Gut permeability
Zonulin is peptide measured in plasma, and which is associated with an impaired
gut barrier. According to Figure 7, plasma zonulin was lower in mice fed the PRE, PRO,
TF and COM treatments, compared to the control (TWD) (p=0.0006, Figure 7).
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Figure 7. Plasma zonulin. Data represent mean ± SE (ng/ml). Different letters represent
significant difference in ANOVA analysis.
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IV. DISCUSSION
Enumeration of probiotic bacteria from the PRO and COM diets was lower than
expected, as a 3-fold increase over the human dose was added to the diets (Table 2). It is
likely the low recovery is due to the process of diet manufacture, and the labile nature of
the added probiotics. Nonetheless, mice consuming these diets received levels between
105 and 106 CFUs per day, which have been associated with significant physiological
effects in previous rodent studies (Poutahidis et al., 2014). It was not expected that there
would be measurable probiotics in the PRE diet, as the only addition to this diet were the
prebiotics. It seems, therefore, that the added powders may contain microbes measured in
the probiotic plate count method (Schoeni, 2013).
Mice consuming the PRO diet consumed significantly more calories per day than
mice consuming the TWD (Table 4). Yet, the increased calorie consumption was not
associated with a greater weight gain, nor metabolic efficiency due to 4-week
intervention.
There were few differences in either the cecal or fecal concentration of SCFAs
due to inclusion of either the prebiotics, probiotics or both. While compared to previous
rodent studies, there were much lower level of treatment which administered and lead to
the insignificant results.
Similarly, as actual dosage for mice was much lower than previous animal study,
there was no significant difference in phylum level abundance or Firmicutes to
Bacteroidetes ratio. Prebiotics and probiotics affected microbiome by increasing
Bifidobacterium longum and Ruminococcus gnavus, respectively. COM showed the same
effect of modification as PRE and PRO due to it combined both prebiotics and probiotics.
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An increasing of Ruminococcus gnavus was found in fecal microbiome in in patients with
Crohn's disease, an inflammatory bowel disease (IBD) (Scaldaferri et al., 2013). It is
suggested that prebiotics might had potential to promote inflammation.
Bifidobacterium longum was one of probiotics supplied in diet in this experiment.
Although the dosage for total probiotics was much lower than out expectation, we
detected an increasing of Bifidobacterium longum in PRO diet compared to TWD, which
suggested the effect of supplements was pronounced. Besides, PRO was associated with
higher level of Clostridium neonatale. It is a strain that digested milk with gas
production. Acetic, lactic and butyric acids are detected as metabolic products (Bernard,
Burdz, Wiebe, Alfa, & Bernier, 2018).
Alpha-diversity and beta-diversity are often used to evaluate the variation of
microbiome composition. The diversity analysis would give a better understanding of
similarity, replacement and richness difference within site and among site (Legendre,
2014). Gut microbiome diversity was negatively associated with weight gain, while it
was positively correlated with fiber intake. Besides, inflammatory bowel diseases (IBD)
patients show an overall decreased gut bacteria diversity with a reduction of the dominant
Firmicutes and Bacteroidetes compared to healthy people(Manichanh et al., 2006; Sokol,
Lay, Seksik, & Tannock, 2008). When mice supplied with prebiotics or probiotics,
enriched microbiome diversity was reported in some studies (W. Cheng et al., 2017; M.
K. Hamilton et al., 2017; Park et al., 2013; Umu et al., 2016). But there was controversy
of non-affect microbiome diversity with a lower dosage or short intervention supplement
(Bai et al., 2016). Human trial reported that microbiome diversity was not affected by
prebiotics or probiotics (Finegold et al., 2014; Holscher et al., 2015; Toscano et al., 2017;
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van Zanten et al., 2014; Vandeputte et al., 2017). We used the reality dosage for mice
rather than megadose, which concluded that the treatment diets did not affect alphadiversity, but affected beta-diversity with exception of TF treatment.
Calprotectin is a Ca2+ binding protein produced by neutrophils (Fallahi et al.,
2013) which is bacteriostatic and fungistatic, and which has a minimum inhibitory
concentration similar to antibiotics (Bunn et al., 2001). Calprotectin is important for the
clearance of infection, as has been shown by the comparison of wild-type and
calprotectin-deficient animals (Urban et al., 2009). Calprotectin can be used to predict
relapses and detect pouchitis in IBD patients, and is used for IBD in undiagnosed,
symptomatic patients(Konikoff & Denson, 2006). Several mice studies showed that
megadose of prebiotics and probiotics supplied with high fat diet improved the
inflammation situation (Carasi et al., 2015; Garcia, Dogi, de Moreno de LeBlanc, Greco,
& Cavaglieri, 2016; Murakami et al., 2015a; Park et al., 2013; Singh et al., 2017).
However, a debate was demonstrated from a 2 weeks synbiotics research which showed
no effect on gut inflammation and permeability (Wilms et al., 2016). In our case, nonsignificant difference of calprotectin suggested that treatment did not affect the
inflammation situation on healthy mice.
All mice were in Chow diet before intervention. Regular chow is composed of
agricultural byproducts. It is a high fiber diet containing complex carbohydrates, with fats
from a variety of vegetable sources(Warden & Fisler, 2008). When the mice were
assigned a relatively high carbohydrates and high fat diet, TWD and other modified
TWD, all treatment showed higher fecal calprotectin compare to Chow diet (Figure 6)
after intervention.
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Zonulin is a 47 kDa protein, with structural similarity to zonula occludens toxin
(ZOT), which is synthesized in the intestine and reversibly regulates the gut barrier
(Fasano, 2000; Fasano et al., 2000). Zonulin has been identified as pre haptoglobin-2
(HP2) which is one of two human alleles of the haptoglobin gene (Tripathi et al., 2009).
Interestingly, HP2, and thus zonulin, is only found in humans (Levy et al., 2010). Yet,
ELISA antibodies to zonulin appear to measure other members of the zonulin family,
such as properdin (A. Fasano, personal communication). A synthetic peptide, AT1001,
contains the receptor-binding motif and is a zonulin inhibitor. In IL-10 knockout mice,
treatment with AT1001 reduces intestinal permeability, and reduces colitis (Arrieta,
Madsen, Doyle, & Meddings, 2009). In mice fed high fat diets, plasma zonulin levels are
positively correlated with hepatic lipid content (Kwon, Lee, Seo, & Kim, 2019), weight
gain and adipose tissue weight (Y. J. Cho, Lee, Seo, Yokoyama, & Kim, 2018). In the
current study, all treatments led a significant reduction in plasma zonulin, compared to
the control. Yet, the effect was not additive in the COM treatment. Furthermore, the
reduction in plasma zonulin was not associated with fecal calprotectin, nor weight gain.
There is no additional effect of Tri-Factor on mice weight and metabolic, gut
fermentation, gut microbiome and inflammation. Additive effect was observed on gut
microbiome when administered prebiotics and probiotics combinedly.
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V. CONCLUSION
Overall, for 1-month intervention, probiotic supplementation increased
Bifidobacterium longum and Clostridium neonatale, while the prebiotic supplementation
increased Ruminococcus gnavus. Combined prebiotic and probiotic administration
increased Ruminococcus gnavus and Bifidobacterium longum as additive effect. The
treatments did not affect alpha diversity, but affected beta-diversity with exception of TriFactor. All treatments were associated with less plasma zonulin, compared to the control
group, indicating an effect on gut permeability. There were no treatment effects on cecal
or fecal short chain fatty acid levels, and the treatments did not affect gut inflammation as
measured by fecal calprotectin.
Physiologically relevant doses of dietary supplements for mice modified gut
microbiome and affect gut permeability, but did not affect gut fermentation and
inflammation.
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